TRAW

Traws Pharma Inc

0.2960

Oct 30 • 3:59 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: COCP AVIR NNVC ENTA SXTP VIR ALGS IMRN SPRO ARMP

Index	-
Market Cap	4.55M
Enterprise Value	-0.47M
Income	-21.57M
Sales	0.00M
Book/sh	0.11
Cash/sh	0.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	7
IPO	Jul 25, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.67
P/C	0.91
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.93
Current Ratio	0.93
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.31
EPS next Y	-1.24
EPS next Q	-0.20
EPS this Y	-246.34%
EPS next Y	-2.92%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	131.12% 64.59%
EPS Y/Y TTM	83.59%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-22.55%
Sales Q/Q	-100.00%
Earnings	Aug 14 AMC
EPS/Sales Surpr.	52.24% -

Insider Own	29.34%
Insider Trans	0.00%
Inst Own	27.10%
Inst Trans	1.36%
ROA	-159.21%
ROE	-433.36%
ROIC	-1275.34%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-25.56%
SMA50	-39.78%
SMA200	-74.62%
Trades

Shs Outstand	15.26M
Shs Float	10.86M
Short Float	6.31%
Short Ratio	1.19
Short Interest	0.69M
52W High	3.23 -90.84%
52W Low	0.29 2.92%
Volatility	14.67% 8.90%
ATR (14)	0.04
RSI (14)	25.01
Beta	1.67
Rel Volume	0.00
Avg Volume	577.76K
Volume	0

Perf Week	-13.58%
Perf Month	-45.72%
Perf Quarter	-37.23%
Perf Half Y	-80.13%
Perf YTD	-73.81%
Perf Year	-88.79%
Perf 3Y	-98.13%
Perf 5Y	-99.66%
Perf 10Y	-100.00%
Recom	3.00
Target Price	1.00
Prev Close	0.30
Price	0.30
Change %	0.00%

Consensus

Hold

Avg. Price Target

$1.00

Implied Upside

+237.8%

Analysts6incl. previous ratings

Rating Distribution4 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 15, 2026	Downgrade	LLadenburg Thalmann	Buy → Neutral
Dec 03, 2025	Initiated	HH.C. Wainwright	Buy	$8	+2,602.7%
Mar 01, 2022	Initiated	LLadenburg Thalmann	Buy	$7	+2,264.9%
May 18, 2021	Initiated	GGuggenheim	Buy	$4	+1,251.4%
Mar 01, 2018	Reiterated	HH.C. Wainwright	Buy	$6 → $7.50	+2,433.8%
Jan 17, 2018	Downgrade	MMaxim Group	Buy → Hold
Oct 09, 2017	Initiated	HH.C. Wainwright	Buy	$6	+1,927.0%
Apr 27, 2017	Initiated	LLaidlaw	Buy	$10	+3,278.4%
Jul 01, 2015	Upgrade	PPiper Jaffray	Neutral → Overweight
May 05, 2015	Initiated	HH.C. Wainwright	Buy	$6	+1,927.0%

Aug-17-26 08:31AM	Traws Pharma shares rise after Q2 loss comes in better than expected (InvestorsHub) -5.43%
Aug-14-26 04:30PM	Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
Jun-22-26 07:00AM	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program (GlobeNewswire)
Jun-18-26 09:35AM	SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls (The Fly) +6.49%
Jun-15-26 07:51AM	Micron, Nebius surge premarket; Traws Pharma tumbles (Investing.com) -40.95%
06:26AM	Loading…
06:26AM	Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study (InvestorsHub)
Jun-12-26 08:07PM	Why Did TRAW Stock Slump 28% After Hours? (Stocktwits)
05:30PM	Traws Pharma Provides Regulatory Update on Influenza Program (GlobeNewswire)
May-27-26 08:45AM	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks (GlobeNewswire)
May-15-26 07:00AM	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results (GlobeNewswire) +15.34%
May-11-26 01:17PM	Here's how much Moderna's stock has rallied off renewed focus on hantavirus research (MarketWatch) -7.34%
May-08-26 01:43PM	There are no hantavirus treatments. The deadly cruise-ship outbreak is a 'wake-up call' to develop some. (MarketWatch) +28.24%
10:30AM	BC-Most Active Stocks (Associated Press)
07:30AM	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections (GlobeNewswire)
Apr-16-26 03:01AM	Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ... (GuruFocus.com)
04:01PM	Loading…
Apr-15-26 04:01PM	Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights (GlobeNewswire) -22.64%
08:15AM	Traws Pharma Announces Up to $60 Million Private Placement Financing (GlobeNewswire)
Apr-14-26 04:17AM	hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy (Proactive)
Feb-19-26 07:30AM	Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza (GlobeNewswire) -20.30%
Jan-26-26 08:30AM	Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza (GlobeNewswire) +15.29%
Jan-13-26 07:00AM	Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID-Eligible and Ineligible COVID-19 Patients (GlobeNewswire) +26.77%
Dec-17-25 06:00AM	Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients (GlobeNewswire) -36.36%
Nov-13-25 07:00AM	Traws Pharma Reports Third Quarter 2025 Results and Business Highlights (GlobeNewswire) -17.29%
Oct-30-25 12:00PM	ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials (PR Newswire) -5.04%
Oct-22-25 06:40PM	Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. (PR Newswire) -10.07%
Oct-14-25 07:00AM	Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 (GlobeNewswire)
Oct-06-25 07:00AM	Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives (GlobeNewswire)
Aug-18-25 07:00AM	Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 (GlobeNewswire) -5.96%
Aug-14-25 07:00AM	Traws Pharma Reports Second Quarter 2025 Results and Business Highlights (GlobeNewswire)
Aug-08-25 07:00AM	Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 (GlobeNewswire)
06:30AM	Loading…
Jun-30-25 06:30AM	Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions (GlobeNewswire)
Jun-03-25 07:00AM	Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib (GlobeNewswire) +31.69%
May-27-25 08:00AM	Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness (GlobeNewswire) +6.87%
May-15-25 07:00AM	Traws Pharma Reports First Quarter 2025 Results and Business Highlights (GlobeNewswire) -11.29%
Apr-01-25 08:50PM	Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript (Seeking Alpha) -6.96% +8.41%
Mar-31-25 09:00AM	Traws Pharma Reports Full Year 2024 Results and Business Highlights (GlobeNewswire)
Mar-28-25 04:30PM	Traws Pharma Announces Management Updates (GlobeNewswire) -6.61%
Mar-26-25 07:30AM	Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET (GlobeNewswire)
Mar-25-25 07:30AM	Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates (GlobeNewswire)
Mar-21-25 07:00AM	Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR (GlobeNewswire)
Mar-03-25 07:00AM	Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil (GlobeNewswire) -30.82%
Feb-28-25 07:00AM	Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule (GlobeNewswire)
Jan-23-25 07:00AM	Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu (PR Newswire) +12.24%
Jan-10-25 05:55PM	Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program (PR Newswire) -9.06%
Dec-30-24 08:00AM	Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval (PR Newswire) -37.26%
Dec-23-24 07:00AM	Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu (PR Newswire) +150.40%
Nov-14-24 04:30PM	Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results (GlobeNewswire) -10.59%
Oct-10-24 01:28PM	Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment (PR Newswire)
Oct-08-24 07:30AM	Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil (GlobeNewswire) -8.40%
Sep-30-24 07:30AM	Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor (GlobeNewswire)
Sep-23-24 09:37PM	Orbimed Advisors LLC Reduces Stake in Traws Pharma Inc (GuruFocus.com) +5.56%
09:48AM	Upcoming Stock Splits This Week (September 23 to September 27) Stay Invested (TipRanks)
Sep-20-24 07:30AM	Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors (GlobeNewswire) -8.32%
Sep-17-24 04:05PM	Traws Pharma, Inc. Announces Special Shareholders Meeting Results (GlobeNewswire) -10.26%
Aug-15-24 07:00AM	Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights (GlobeNewswire)
Aug-14-24 04:30PM	Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET (GlobeNewswire) -7.25%
May-23-24 08:00AM	Traws Pharma's ICAR Poster Highlights Potency of COVID-19 Candidate (GlobeNewswire)
May-16-24 09:29AM	Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 08:00AM	Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy (GlobeNewswire)
Apr-02-24 07:15AM	Traws Pharma Announces New Employee Inducement Grants (GlobeNewswire)
07:00AM	Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company (GlobeNewswire)
Mar-08-24 08:00AM	Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma (GlobeNewswire) -10.63%
Dec-08-23 04:05PM	Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's (GlobeNewswire) +25.10%
Nov-28-23 08:00AM	Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-16-23 08:44AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:05PM	Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Nov-02-23 10:37AM	Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL (GlobeNewswire)
Oct-26-23 08:52PM	Lab Notes: Philadelphia health care investment firm closes two funds valued at over $500M (American City Business Journals)
Oct-24-23 08:00AM	Onconova Expands Leadership Team with Two Key Appointments (GlobeNewswire)
Oct-19-23 08:00AM	Promising Preclinical Narazaciclib Data Presented at MCL Meeting (GlobeNewswire)
Oct-12-23 08:00AM	Encouraging Rigosertib Data Presented at EADV as Late Breaker (GlobeNewswire)
Sep-28-23 08:00AM	Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress (GlobeNewswire)
Sep-06-23 08:00AM	Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-13-23 05:36AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 07:57AM	Q2 2023 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.87%
Aug-10-23 04:05PM	Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-17-23 06:59AM	Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation (Simply Wall St.)
Jun-14-23 08:00AM	Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma (GlobeNewswire)
Jun-05-23 08:00AM	Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-25-23 08:00AM	Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade (GlobeNewswire)
May-16-23 06:29AM	Q1 2023 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 05:35PM	Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.60%
04:18PM	Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-12-23 08:00AM	Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer (GlobeNewswire) +5.04%
May-11-23 08:00AM	Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer (GlobeNewswire) -8.46%
May-08-23 08:00AM	Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium (GlobeNewswire)
May-04-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire) -6.47% +7.69%
Apr-19-23 09:00AM	Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting (GlobeNewswire)
Apr-06-23 04:05PM	Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder (GlobeNewswire)
Mar-23-23 08:00AM	Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib (GlobeNewswire)
Mar-18-23 02:06AM	Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:17AM	Q4 2022 Onconova Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:04PM	Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +7.09%
Mar-15-23 08:00AM	Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting (GlobeNewswire)
Mar-09-23 04:05PM	Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Apr 16 '26	Buy	1.67	597,729	998,207	1,203,250	Apr 28 09:41 PM

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

M.A.Dr. Iain D. Dukes DPHIL

COO & DirectorDr. Nikolay Savchuk Ph.D.

Chief Medical Officer of OncologyDr. Victor Mandia Moyo M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRAW

Traws Pharma Inc

Upgrade your Finviz experience